DataMeds AI, Inc. (MEDS) · Oct 26, 2026 · Material agreement

DataMeds AI acquisition LOI adds IP but leaves holders 10.5%

89.5% ownership transfer — New holders ~89.5%; existing holders ~10.5%

DataMeds AI’s acquisition LOI broadens its healthcare stack, but proposed stock issuance would leave existing holders with only about 10.5%.

DataMeds is still in an early build-out phase: it is combining Health Lives Here, a 6,500-pharmacy network, and the recently acquired Helomics diagnostics business rather than operating as a scaled healthcare platform; its Q2 update reported a $1.779 million revenue quarter alongside an $18.363 million operating loss.

The proposed platform becomes broader, but not yet more executable. The new LOI adds REBOOT’s behavioral-health technology and products, expands the Datavault license, brings in additional QLPM delivery and biometric intellectual property, and restructures the planned Tollo/Health Lives Here combination. It supersedes the July LOI, which had expired on September 30, so the direction was already known; the new information is the broader package, added royalties, and revised ownership terms. 〔0〕

The economic cost is a transfer of control to the counterparties. Upon closing, EOS, Scilex, Datavault, Fortitude, HBA, THI and REBOOT are expected to receive approximately 89.5% of the fully diluted company, leaving existing public holders with about 10.5%. 〔1〕 The package also adds ongoing revenue royalties—6% to REBOOT and 5% each to EOS and Scilex—so the proposed assets would come with continuing claims on future revenue. 〔2〕

This remains a proposal, not a completed acquisition. The LOI is expressly non-binding except for selected provisions, and closing still depends on definitive agreements, due diligence, a fairness opinion, stockholder and Nasdaq approvals, and reducing liabilities to no more than $2 million. The company therefore has a more ambitious strategic blueprint, but the filing does not establish that the assets are producing meaningful revenue or that the transaction can close on the targeted timetable.

Bottom line: This advances DataMeds’ healthcare-platform story by adding more technology and operating pieces, but it does so through a highly dilutive, control-shifting proposal that is still several approvals and definitive contracts away from reality.

What to watch next

Definitive agreements and Q4 2026 closing

Original filing on SEC EDGAR

More DataMeds AI, Inc. news

DataMeds AI acquisition LOI adds IP but leaves holders 10.5% | MEDS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.